AstraZeneca Sues Mylan Over Entocort ANDA
According to the complaint, filed Tuesday in the U.S. District Court for the District of Delaware, Mylan sent AstraZeneca a letter on June 9 saying that it had filed an abbreviated new drug application with the Food and Drug Administration to make generic Entocort.
AstraZeneca said that the proposed generic would infringe two of its patents. Mylan said...
To view the full article, register now.